Drugs / WP1302
last change Mar 2026 re-read 2 minutes ago

WP1302

Developed for
Graves disease

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06240455 Comparator Mar 2026 → Mar 2029 Graves disease Worg Biotherapeutics Inc. Suspended No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as WP1302 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06240455
Route Subcutaneous “WP1302 or placebo by subcutaneous (S.C.) injection” NCT06240455